Oncopeptides
Manufacturing · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Luntmakargatan 46 Vån 7, Stockholm, Stoc...Phone Number
+46 86152040Website
www.oncopeptides.comRevenue
<$5 MillionStock Symbol
ONCO.STIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Oncopeptides
Oncopeptides AB is a global biotech company dedicated to the research, development, and commercialization of targeted therapies for challenging hematological diseases. The company is driven by science and innovation, aiming to improve the lives of patients with unmet medical needs. Their flagship product, Pepaxti, is designed for the treatment of multiple myeloma, and they are expanding their pipeline to include therapies for glioblastoma. Oncopeptides serves healthcare providers and patients seeking advanced treatment options in oncology.Explore more
Oncopeptides Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncopeptides your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Oncopeptides, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Oncopeptides launches new products
Check if Oncopeptides has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Oncopeptides
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Oncopeptides had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Oncopeptides has new funding data
Check out if Oncopeptides is spiking on competitors!
Earning: See what the market has to say on Oncopeptides recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Oncopeptides is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncopeptides is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncopeptides.
Oncopeptides Tech Stack
A closer look at the technologies used by Oncopeptides
Most Recent Scoops
Project
Oncopeptides announced that Pepaxti has been included in the EHA-EMN guidelines with a 1B recommendation, reinforcing its positioning in the multiple myeloma treatment landscape.
Earnings
Oncopeptides has reported net sales of SEK 25.4 million for Q1 2026, reflecting a 91% increase compared to Q1 2025.
Earnings, Finance
Earnings
Oncopeptides has reported a 99% gross margin and an 11% year-over-year reduction in operating expenses for Q1 2026, alongside 91% revenue growth year-over-year, reflecting improved operating leverage and cost discipline.
Earnings, Finance, Financial Operations
Earnings
Oncopeptides has reported that Italy achieved close to 100% regional access for Pepaxti in Q1 2026, supported by a positive clinical experience and a centralized prescriber base, with Pepaxti gaining a strong position in the fourth line of treatment.
Pharmaceuticals, Clinical Operations
Project
Regulations
Oncopeptides News & Media
Oncopeptides AB (publ) (ONPPF) Q4 2025 Sales/Trading Call Transcript
Oncopeptides AB (publ) (ONPPF) Q4 2025 Sales/Trading Call January 16, 2026 3:00 AM ESTCompany ParticipantsSofia Heigis - Chief Executive OfficerHenrik...Cardiac Amyloidosis Treatment Market Emerging Trends | Eidos Therapeutics, Oncopeptides AB
Examining growth in the cardiac amyloidosis market with emerging therapies and improved diagnostics for better patient outcomes. BURLINGAME, CA, UNITED STATES, October 24, 2024 /EINPresswire.com/ -- A new report published by CoherentMI, titled " …Oncopeptides expands on WODA partnership with addition of Africa and Eurasia to provide Pepaxti to Patients
Oncopeptides expands on WODA partnership with addition of Africa and Eurasia to provide Pepaxti to PatientsOncopeptides Chief Financial Officer Henrik Bergentoft takes office today - MarketScreener
Stockholm – November 13, 2023 – Oncopeptides AB , a biotech company focused on difficult to treat cancers, today announces that Henrik Bergentoft today takes office as the company´s new Chief...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncopeptides
Sign Up For FreeTo access detailed company insights
Oncopeptides AB is a global biotech company dedicated to the research, development, and commercialization of targeted therapies for challenging hematological diseases. The company is driven by science and innovation, aiming to improve the lives of patients with unmet medical needs. Their flagship product, Pepaxti, is designed for the treatment of m... Read More
